Specialist Fund Concentration in DMD Treatments: Pipeline and Mechanisms
April 9, 2026
Duchenne muscular dystrophy has attracted an unusual concentration of specialist biotech hedge fund interest. We mapped interventional trials across 10 companies and overlaid beneficial ownership data from 18 specialist funds to show where that consensus sits and why.